RadNet, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter earnings report. RadNet operates outpatient imaging centers and related imaging software and AI businesses; it had 347 centers across seven states at year-end.
Financial performance and position
- Revenue: GAAP total revenue was $1.315 billion, up 22.7% from $1.072 billion in 2020. Provider relief funding of $9.1 million is reported separately; including it, revenue and relief funding totaled $1.324 billion, up 20.6% from $1.098 billion in 2020. Same-center revenue including relief funding rose 14.9%, with same-center procedure volume up 20.0%.
- Profit and margins: Operating income was $82.6 million (6.3% of revenue), versus $35.7 million (3.3%) in 2020. Net income was $44.3 million, including $19.6 million attributable to noncontrolling interests; net income attributable to RadNet common stockholders was $24.7 million, or $0.47 basic and $0.46 diluted per share. In 2020, RadNet reported a $14.8 million attributable loss, or $0.29 per share.
- Adjusted EBITDA: $218.9 million, compared with $139.5 million in 2020. This is a non-GAAP measure and includes adjustments described in the filing.
- Cash flow and investment: Operating cash flow was $149.5 million, down from $233.8 million; 2020 included $39.5 million of CMS advance payments. Investing cash outflow was $221.5 million, including $137.9 million in property and equipment purchases and $77.7 million for imaging business acquisitions. Financing cash inflow was $104.7 million. Company-defined free cash flow was $65.1 million versus $14.0 million.
- Liquidity: Cash and equivalents were $134.6 million, up from $102.0 million. Working capital, excluding current operating lease liabilities, was $14.9 million versus negative $61.9 million. Including current operating lease liabilities, current liabilities exceeded current assets by approximately $50.5 million.
- Debt and commitments: Term-loan face value was $767.9 million ($754.7 million carrying value, net of discount); no revolving credit borrowings were outstanding. Available revolving capacity was $187.2 million under the Barclays facility and $30.0 million under the SunTrust facility. Operating lease liabilities totaled $643.1 million. The company reported compliance with credit-facility covenants at year-end.
- Other balance-sheet data: Total assets were $2.058 billion, total liabilities $1.712 billion, and total equity $346.2 million. Goodwill was $513.8 million.
Changes versus 2020
- Imaging volumes recovered to pre-pandemic levels by year-end, supporting higher revenue and operating income. The company added 27 centers through acquisitions and closed or sold 12.
- Operating expenses increased 16.9% to $1.242 billion, slower than revenue growth. The year included $19.7 million of one-time lease-abandonment charges as RadNet consolidated some centers and reduced office space.
- Interest expense rose to $48.8 million from $45.9 million, while company-reported adjusted interest expense on debt and lease obligations declined. A $21.7 million noncash gain from the ineffective portion of interest-rate swaps benefited reported results.
- Cash from operations declined, partly because 2020 included CMS advances and 2021 included repayment/application of prior advances and other working-capital movements.
Outlook, risks and unusual items
- The filing provides no specific numeric financial guidance. Management said procedure volumes had returned to pre-COVID levels and anticipated ongoing benefit from cost-saving measures, while continuing to pursue organic growth, acquisitions, joint ventures and AI/software development.
- COVID-19 recurrence, reimbursement reductions, capitation utilization risk, competition, staffing and radiologist availability, acquisition integration, and high fixed costs could pressure volumes, margins and cash flow.
- RadNet highlighted substantial debt, variable-rate exposure and covenant restrictions. Its $500 million of interest-rate swaps were not fully effective as cash-flow hedges; changes in fair value can create earnings volatility. A hypothetical 1% increase in the applicable Eurodollar rate on the First Lien Term Loans was estimated to increase annual interest expense by $7.2 million.
- Other material risks include healthcare regulation and reimbursement compliance, corporate-practice-of-medicine restrictions, cybersecurity and privacy incidents, and potential legal or governmental claims. The company disclosed a prior unauthorized network access incident and noted that cyber insurance may not cover all losses.
- Revenue recognition estimates for contractual allowances and patient price concessions were identified by the auditor as a critical audit matter. The auditor issued unqualified opinions on the financial statements and internal controls.
- After year-end, RadNet acquired certain radiology practice assets for $13.0 million and acquired Dutch AI companies Aidence and Quantib for a combined $95.0 million, paid through cash and common shares. These transactions were not included in 2021 results.
Key facts for investors to verify
- Whether procedure growth and margins remain durable after the post-pandemic recovery, excluding provider relief funding and other nonrecurring items.
- How operating cash flow and free cash flow develop relative to acquisition spending, capital expenditures, lease commitments and debt service.
- Debt repayment, refinancing and interest-rate exposure, including the impact of benchmark-rate transition and hedge accounting volatility.
- Actual performance, integration costs and commercial adoption of the AI acquisitions, including the $95.0 million post-year-end investment.
- Effects of Medicare and commercial reimbursement changes, capitation utilization, and the company’s revenue-estimation and collections assumptions.